Doravirine

Doravirine
Clinical data
Trade names	Pifeltro
Other names	MK-1439
AHFS/Drugs.com	Monograph
MedlinePlus	a618048
License data	US DailyMed: Doravirine;
Routes of; administration	By mouth
ATC code	J05AG06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 3-Chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydro-3-pyridinyl}oxy)benzonitrile;
CAS Number	1338225-97-0;
PubChem CID	58460047;
DrugBank	DB12301;
ChemSpider	28424197;
UNII	913P6LK81M;
KEGG	D10624;
ChEMBL	ChEMBL2364608;
PDB ligand	2KW (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID30158386 ;
ECHA InfoCard	100.234.454
Chemical and physical data
Formula	C17H11ClF3N5O3
Molar mass	425.75 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cn1c(n[nH]c1=O)Cn2ccc(c(c2=O)Oc3cc(cc(c3)Cl)C#N)C(F)(F)F;
	InChI InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28); Key:ZIAOVIPSKUPPQW-UHFFFAOYSA-N;

Doravirine, sold under the brand name Pifeltro, is a non-nucleoside reverse transcriptase inhibitor medication developed by Merck & Co. for use in the treatment of HIV/AIDS.

Doravirine was approved for medical use in the United States in August 2018.

Doravirine is available in fixed-dose combinations with other HIV drugs such as doravirine/lamivudine/tenofovir (sold under the brand name Delstrigo).